

Hercília Guimarães¹
Gustavo Rocha¹
Gabriela Vasconcellos¹
Elisa Proença²
Maria Luísa Carreira³
Maria do Rosário Sossai⁴
Benvinda Morais⁴
Isabel Martins⁵
Teresa Rodrigues⁵
Milton Severo⁵

Factores de risco de displasia broncopulmonar em cinco unidades portuguesas de cuidados intensivos neonatais

Risk factors for bronchopulmonary dysplasia in five Portuguese neonatal intensive care units

Recebido para publicação/received for publication: 09.04.23
Aceite para publicação/accepted for publication: 09.11.05

Resumo

A displasia broncopulmonar (DBP) é multifactorial. Prematuridade, doença da membrana hialina, oxigénio, ventilação mecânica, inflamação e canal arterial são alguns dos factores na sua patogénese

Objectivo: Avaliar a prevalência da DBP e seus factores de risco em cinco unidades portuguesas, para implementar boas práticas no tratamento deste doentes.

Material e métodos: 256 recém-nascidos (RN) com idade gestacional (IG) <30 semanas e/ou peso <1250 g internados em cinco unidades portuguesas, entre 2004 e 2006, foram estudados. Foi recolhida a informação clínica dos processos. A DBP foi definida como a necessidade de oxigénio às 36 semanas de idade pós-concepcional.

Abstract

The pathogenesis of bronchopulmonary dysplasia (BPD) is clearly multifactorial. Specific pathogenic risk factors are prematurity, respiratory distress, oxygen supplementation, mechanical ventilation (MV), inflammation, patent ductus arteriosus (PDA), etc.

Aim: To evaluate BPD prevalence and to identify risk factors for BPD in five Portuguese Neonatal Intensive Care Units in order to develop better practices the management of these newborns.

Material and methods: 256 very low birth weight infants with gestational age (GA) <30 weeks and/or birthweight (BW) <1250 g admitted in five Portuguese NICUs, between 2004 and 2006 were studied. A protocol was filled in based on clinical information regis-

¹ Maternidade Júlio Dinis (Director: Dr. José Pombeiro), Porto

² Hospital de Santo António (Director Dr^a. Paula Cristina Fernandes), Porto

³ Hospital Fernando Fonseca (Director Dr^a Rosalina Barrosos), Lisboa

⁴ Hospital Pedro Hispano (Dr^a Agostinha Souto), Porto

⁵ Serviço de Epidemiologia (Director Professor Henrique de Barros), Faculty of Medicine of Porto University, Portugal

Hospital de S. João (Director: Professora Doutora Hercília Guimarães), Porto
e-mail: herciliaguimaraes@gmail.com

Resultados: A prevalência da DBP foi de 12,9%. O seu risco diminuiu de 46% por semana de IG e de 39% por 100g de peso. O risco de DBP foi maior entre os RN com baixo peso (OR adj = 0,73, 95% CI=0,57-0,95), doença da membrana hialina grave (OR adj = 9,85, 95% CI=1,05-92,35), com sépsis (OR adj = 6,22, 95% CI=1,68-23,02), com maior duração de ventilação (42 vs 3 dias, respectivamente nos RN com e sem DBP, $p < 0,001$) e maior duração de $FiO_2 \geq 0,30$ (85 vs 5 dias, respectivamente nos doentes com e sem DBP, $p < 0,001$).

Comentários: Os factores de risco de DBP mais relevantes foram o baixo peso, a doença da membrana hialina grave, a duração da ventilação mecânica e da oxigenoterapia e a sépsis. A implementação das boas práticas para reduzir a lesão pulmonar nos RN deve ser dirigida para melhorar as práticas que reduzem estes factores de risco.

Rev Port Pneumol 2010; XVI (3): 419-430

Palavras-chave: Displasia broncopulmonar, recém-nascidos pré-termo, unidades de cuidados intensivos neonatais, doença da membrana hialina, ventilação mecânica, oxigenoterapia, factores de risco, boas práticas.

tered in the hospital charts. BPD was defined as oxygen dependency at 36 weeks of postconceptional age.

Results: BPD prevalence was 12.9% (33/256). BPD risk decreased 46% per GA week and of 39% per 100g BW. BPD risk was significantly higher among newborns with low BW (adj OR= 0.73, 95% CI=0.57-0.95), severe hyaline membrane disease (adj OR= 9.85, 95% CI=1.05-92.35), and those with sepsis (adj OR=6.22, 95% CI=1.68-23.02), those with longer duration on ventilatory support (42 vs 3 days, respectively in BPD and no BPD patients, $p < 0.001$) and longer duration of $FiO_2 \geq 0.30$ (85 vs 5 days, respectively in BPD and no BPD patients, $p < 0.001$).

Comments: The most relevant risk factors were low birth weight, severe hyaline membrane disease, duration of respiratory support and oxygen therapy, and nosocomial sepsis. The implementation of potentially better practices to reduce lung injury in neonates must be addressed to improve practices to decrease these risk factors.

Rev Port Pneumol 2010; XVI (3): 419-430

Key-words: Bronchopulmonary dysplasia, preterm infants, neonatal intensive care, prematurity, hyaline membrane disease, mechanical ventilation, oxygen therapy, risk factors, better practices.

Introduction

The pathogenesis of Bronchopulmonary dysplasia (BPD) is clearly multifactorial and specific pathogenic known risk factors are prematurity, hyaline membrane disease (HMD), oxygen supplementation, mechanical ventilation (MV), inflammation and infection, patent ductus arteriosus (PDA), among others¹. Despite extensive research

aimed at identifying risk factors of BPD and devising preventative therapies, many questions about the aetiology and pathogenesis of BPD remain².

With the advent of surfactant, prenatal steroids and improving technology, the survival rate of extremely low birth weight (ELBW) infants has improved dramatically. Despite these improvements, however, the

incidence of BPD in ELBW infants has remained stable over last decades and contributes significantly to the morbidity and mortality seen in these preterm infants. Rates of BPD vary widely. In a recent study, where BPD was defined as oxygen need at 36 weeks postconceptional age, the incidence was 52% in infants with birth weight of 501-750g, 34% in infants with birth weight of 751-1000g, 15% in infants with birth weight of 1001-1200g, 7% in infants with birth weight of 1201-1500g³.

In these very preterm babies, BPD (New BPD) is quite different from the BPD described in the most mature babies (Old or Classic BPD), because the delivery occurred in the very immature stage of the normal lung development^{4,6}. This can explain the histological characteristic features showing rarefaction of the pulmonary vascular bed, reduced alveolarization, less fibrosis and less bronchial metaplasia. In this "New" BPD the immaturity seems to be much more important than external factors. However oxygen toxicity, volu and barotrauma of mechanical ventilation, inflammation and/or infection (biotrauma) and increased pulmonary flow and lung oedema are also very important risk factors to be taken into account in these immature babies¹.

Our aim was to evaluate the prevalence of BPD and to identify risk factors for BPD in preterm babies of five Portuguese NICUs in order to develop better practices in the management of these newborns.

Patients and methods

Very low birth weight (VLBW) infants with gestational age (GA) less than 30 weeks and/or birth weight (BW) less than 1250 grams

admitted in five Portuguese NICUs, between 1st January 2004 and 31st December 2006 and alive at 36 weeks of PCA were included. VLBW infants with *major* malformations, grade IV intraventricular haemorrhage in the first week of life, metabolic or neuromuscular disease were excluded. A protocol was filled in based on clinical information registered in the hospital charts: maternal history, newborn demographical and clinical data, mechanical ventilation (MV), oxygen supplementation and fluid administration until 36 weeks of postconceptional age (PCA). Neonatal sepsis, patent ductus arteriosus (PDA), necrotizing enterocolitis (NEC), retinopathy of prematurity (ROP), intraventricular haemorrhage (IVH), periventricular leukomalacia (PVL) were also registered.

BPD was defined as oxygen dependency at 36 weeks of PCA and had characteristic chest radiographs⁷. Gestational age (in this study we considered the completed weeks) was assessed by menstrual age (women with regular menstrual cycles), ultrasound examination (when a discrepancy of two or more weeks existed between the age derived by menstrual dating and the age derived sonographically, or in the absence of a menstrual date)⁸ or the New Ballard Score (in the absence of obstetrical indexes)⁹. Respiratory distress syndrome (hyaline membrane disease) was defined according to Rudolf AJ *et al* criteria¹⁰. Proven neonatal sepsis was defined as any systemic bacterial or fungal infection documented by a positive blood culture. Hemodynamically significant patent ductus arteriosus was diagnosed on the basis of the echocardiographic findings. The criteria of Bell were used for the diagnosis and staging of necrotizing enterocolitis¹¹. Stag-

ing of retinopathy of prematurity was done according to the International Classification^{12,13}. Intraventricular haemorrhage was classified according to Papile LA¹⁴. Periventricular leukomalacia was classified according to de Vries L and Rennie JM¹⁵.

Odds ratios were used to measure the magnitude of the association between BPD and BPD risk factors. Crude and adjusted Odds ratios were calculated using unconditional logistic regression.

The Breslow-Day and Taron's statistics were computed for the test of homogeneity of the odds ratios among the five hospitals.

A *p* value <0.05 was considered significant.

Statistical analysis was performed using the statistical package SPSS 17.0.

Results

A sample of 256 newborns met inclusion criteria. We observed a decrease in BPD risk of 46% per week of GA and of 39% per 100g BW. The prevalence of BPD was 12.9% (33/256).

Out of 256 infants, 143 (56%) had HMD. Two (6.7%) infants without HMD and in 81 (41.3%) with HMD developed BPD.

The risk of BPD was higher among preterm infants with low GA (crude OR=0.54, 95% CI=0.43-0.70); low birth weight (crude OR=0.61, 95%CI=0.50-0.74); intrauterine growth restriction (crude OR=1.23, 95%CI=0.50-3.04), those with HMD (crude OR=7.15, 95%CI=1.48-34.41, for mild HMD; crude OR=9.72, 95%CI 2.09-45.24, for moderate HMD and crude OR=20.25, 95%CI=3.81-107.65, for severe HMD), ventilated newborns (crude OR=5.97, 95%CI=1.39-25.7), those with $FiO_2 \geq 0.4$ (3.92, 95%CI=1.60-9.58), with

higher daily mean fluid administration (crude OR=1.01, 95%CI=1.01-1.10) and those with nosocomial sepsis crude (OR=6.41, 95%CI=2.54-16.14) and PDA (crude OR=4.48, 95%CI=2.10-9.58). After adjustment for all variables in the model, only OR for birth weight, severe HMD and sepsis (early and late or nosocomial) were significantly associated with BPD (Table I). The median of the duration of mechanical ventilation was 42 days in BPD patients and 3 in non BPD patients, *p*<0.001. The median of the duration of oxygen therapy was 85 days in BPD patients and 5 in non BPD patients, *p*<0.001 (Table II).

From the associated pathology we looked for (NEC, ROP; IVH and PVL) only ROP was significantly associated with BPD, *p*<0.001 and OR=3.48 (Table III).

Discussion

Despite increased knowledge and improving technology, BPD rates have remained high. Its incidence varies among institutions, ranging between 15 and 50% of all VLBW infants¹⁶. These differences can be due in part to the definition of BPD and to the decision to administer oxygen that is not uniform, because there is no consensus in the literature and neonatologists have widely divergent practices regarding oxygen saturations targets. In this study we used the BPD definition of oxygen dependency at 36 weeks of PCA.

To decrease the big differences, efforts must be made to identify infants treated with oxygen who are able to maintain saturations exceeding 90% in room air^{17,18}. After 4 decades since the original description by Northway, its clinical presentation, evidence

FACTORES DE RISCO DE DISPLASIA BRONCOPULMONAR EM CINCO UNIDADES PORTUGUESAS DE CUIDADOS INTENSIVOS NEONATAIS

Hercília Guimarães, Gustavo Rocha, Gabriela Vasconcelos, Elisa Proença, Maria Luísa Carreira, Maria do Rosário Sossai, Benvinda Morais, Isabel Martins, Teresa Rodrigues, Milton Severo

Table I – Bronchopulmonary risk factors

	BPD n=33	no BPD n=223	Crude OR (95% CI)	Adjusted OR* (95% CI)
Gestational age (weeks) P50 (P25-P75)	26 (25-27)	29 (27-29)	0.54 (0.43-0.70)	0.84 (0.59-1.16)
Birth weight (grams) P50 (P25-P75)	770 (700-990)	1120 (930-1250)	0.61 (0.50-0.74)	0.73 (0.57-0.95)
Sex (M/F)	17/16	114/109	0.98 (0.47-2.05)	–
Clinical chorioamnionitis	3 (9%)	51 (22.8%)	0.35 (0.10-1.21)	–
Intrauterine growth restriction	7 (21.2%)	40 (17.9%)	1.23 (0.50-3.04)	–
Mild HMD	9 (30)	51 (26)	7.15 (1.48-34.41)	3.9 (0.54-28.84)
Moderate HMD	12 (40)	50 (25.5)	9.72 (2.09-45.24)	3.28 (0.40-2.18)
Severe HMD	7 (23.3)	14 (7.1)	20.25 (3.81-107.65)	9.85 (1.05-92.35)
Mechanical ventilation	31 (93.9%)	161 (72.2%)	5.97 (1.39-25.7)	0.45 (0.51-4.08)
FiO ₂ >0.40	22 (66.6%)	93 (41.7%)	3.92 (1.60-9.58)	0.87 (0.24-3.13)
Fluids, 1 st week, ml/kg/day (P25-P75)	114 (84-145)	111 (77-146)	1.05 (1.01-1.10)	1.01 (0.95-1.07)
Early and late sepsis	27 (81.8%)	92 (41.3%)	6.41 (2.54-16.14)	6.22 (1.68-23.02)
Patent ductus arteriosus	22 (66.6%)	77 (34.5%)	4.48 (2.10-9.58)	2.54 (0.82-7.85)

* Adjusted for all variables in the model. MV – mechanical ventilation; HMD – Hyaline membrane disease

Table II – Duration of mechanical ventilation and FiO₂ in patients with and without BPD

	BPD (n=33)	no BPD (n=223)	p
Mechanical ventilation, days (P25-75)	42 (25-63)	3 (0-8)	<0.001
FiO ₂ , days (P25-75)	85 (71-100)	5 (2-30)	<0.001

Table III – Associated pathology with bronchopulmonary dysplasia

	BPD n (%)	No BPD n (%)	p	crude OR (95% CI)	adjusted OR* (95% CI)
NEC (>IIA)	3 (3.0)	3 (1.3)	0.420	–	–
ROP (>3)	8 (24.2)	8 (3.6)	<0.001	8.6 (2.97-24.92)	3.48 (1.06-11.41)
IVH (III-IV)	2 (6.1)	13 (5.8)	1.000	–	–
PVL	1 (3.0)	12 (5.4)	1.000	–	–

* Adjusted for gestational age and birth weight. NEC – necrotizing enterocolitis; ROP – retinopathy of prematurity; IVH – intraventricular haemorrhage; PVL – periventricular leukomalacia

about its pathogenesis and epidemiology have changed and the understanding of this process has provided new possibilities for BPD prevention.

The prevalence of BPD in our study was 12.9%; a similar frequency of 15% has been published in infants with birth weight of 1001-1200g³. In VLBW infants Portugal the frequency of BPD is of 20 %¹⁹. However these frequencies must be compared

taking into account the mortality rate observed in these NICUs. In this study the global rate of mortality in this group of pre-term infants was 17.8%.

The incidence of BPD in premature infants is inversely proportional to gestational age and birth weight^{16,20}. We observed a decrease in BPD risk of 46% per GA week and of 39% per 100g BW; we found no significant difference between sexes.

Chorioamnionitis – Inflammation (and infection), either antenatal or postnatal, is likely to be a major trigger for the lung inflammation that plays a role in the pathogenesis of BPD^{1,21,22}. Airways remodelling can occur as a consequence of lung injury^{23,24}.

Although there is a recent evidence that premature infants born to mothers with chorioamnionitis are at increased risk of developing BPD^{21,23}, other studies couldn't confirm this association^{25,26}. In this study chorioamnionitis was not analysed because placental histological data, essential for the chorioamnionitis diagnosis, were missing in many patients' charts.

Intrauterine growth restriction – Preterm infants with intrauterine growth retardation (IUGR) reveal an increased risk of perinatal mortality and neonatal morbidity, namely for the development of acute and chronic pulmonary disorders, i.e. BPD^{20,27-28}. Another recent study showed that AGA infants of 26-28 weeks' gestation with birth weights below the median had an increased risk of developing BPD²⁹.

In this study, IUGR was not identified as a risk factor of BPD, registered in 21.2% and 17.9% of the babies, respectively with and without the disease. This may be due in part to the fact of the small size of the sample to identify risk factors of this multifactorial disease. However, a recent study shows that the most significant variable that can be correlated to the long-term outcome is the gestational age²⁰.

Hyaline membrane disease – HMD or respiratory distress syndrome is a common cause of morbidity and mortality associated with premature delivery. In uncomplicated cases, typically seen in more mature infants, recovery is rapid and infants generally no

longer require oxygen or ventilatory support after the first week of life. The most premature infants are at greatest risk of severe RDS and frequently develop complications, including central nervous system haemorrhage, PDA, air leak, and infection, which contribute to prolonged requirements of oxygen and ventilatory support and consequently preterm infants develop BPD³⁰. BPD rarely develops, nowadays, in infants greater than 32 weeks of gestation, being inversely proportional to GA and BW¹⁶. The present study shows, as we expected, that severe HMD was significantly associated with BPD. The increased vulnerability of extremely preterm infants relates to the immature state of the lung development that can be easily damaged by mechanical ventilation and oxygen, required to ensure survival. The premature birth plus therapeutic interventions can disrupt the normal progression of lung architecture, related to the development of alveoli and lung vasculature. This produces significant sequelae, inhibition of acinar development and reduction in number of alveoli and capillaries, seen in the "New" BPD. In both, Classic and New BPD the lung immaturity is a *major* BPD risk factor¹.

Mechanical ventilation – Invasive ventilation via the endotracheal tube is one of the most common therapeutic interventions performed in preterm infants with respiratory failure. Mechanical ventilation using conventional or high-frequency ventilation and surfactant therapy have become the standard of care in management of preterm infants with RDS. However, BPD remains as a major morbidity with adverse pulmonary and non pulmonary outcomes in preterm infants despite these interventions.

Ventilator-associated lung injury appears to be related to the duration of invasive ventilation via the endotracheal tube rather than the mode of ventilation. Randomized controlled trials comparing conventional mechanical ventilation and high-frequency ventilation, using 'optimal ventilatory strategies', have shown no significant difference in rates of BPD. Use of noninvasive ventilation, such as N-CPAP has shown a significant decrease in post extubation failure as well as reduced incidence of BPD³¹⁻³³.

In the present study the risk of BPD was significantly higher among ventilated newborns, but after adjustment for all variables in the model in MV the difference was not statistically significant (Table I). However the median of the duration of mechanical ventilation was 42 days in BPD patients and 3 in non BPD patients, $p < 0.001$ (Table II). This aspect confirms the importance of MV as a risk factor of BPD and should be taken into account in the management of these preterm infants.

N-CPAP or early surfactant therapy with early extubation onto N-CPAP rather than continued mechanical ventilation has been adopted by many centres, particularly in Scandinavia, as part of the treatment of newborns with respiratory distress syndrome. It has been suggested that BPD is less of a problem in centres adopting such a policy. Results from randomized trials suggest prophylactic or early N-CPAP may reduce BPD, but further studies are required to determine the relative contributions of an early lung recruitment policy, early surfactant administration and N-CPAP in reducing BPD. In addition, the optimum method of generating and delivering N-CPAP needs to be determined. The efficacy

of N-CPAP in improving long-term respiratory outcomes needs to be compared with the newer ventilator techniques with the optimum and timing of delivery of surfactant administration^{34,35}.

Oxygen – Oxygen is the most commonly used therapy in NICUs as an integral part of respiratory support. The objective of oxygen therapy is to achieve adequate delivery of oxygen to the tissue without creating oxygen toxicity. However current evidence for optimal oxygen saturation for extremely premature infants is scarce. We still know very little about how much oxygen these babies actually need, or how much oxygen is safe to give, especially in the first few weeks of life³⁵⁻³⁸.

In the STOP-ROP trial (Supplemental Therapeutic Oxygen for Prethreshold Retinopathy), babies in supplemental oxygen arm (target saturations of 96-99%) had evidence of adverse pulmonary outcome comparing with the conventional oxygen arm (target saturations of 89-94%)³⁹.

Recent studies of Saugstad and co-workers showed that in ELBW infants, oxygen saturations levels should be kept between 85 and 93% or possibly between 88 and 95%, but should definitely not exceed 95% and fluctuations should be avoided³⁵.

In this study the risk of BPD was significantly higher among newborns with $FiO_2 \geq 0.4$, but after adjustment for all variables in the model, the difference was no longer statistically significant (Table I). However the median of the duration of oxygen therapy was 85 days in BPD patients and 5 in no BPD patients, $p < 0.001$ (Table II). This aspect confirms the importance of the high FiO_2 as risk factor of BPD and should be taken into account in the management of these preterm infants.

To avoid hyperoxemia is an important goal during respiratory support and neonatal exposure to 100% oxygen is almost never necessary. Much lower FiO_2 during the neonatal period can also lead to oxygen toxicity if oxygen is used when it is not necessary. Even brief neonatal exposures to pure oxygen must be avoided⁴⁰.

Recent data show that a lower FIO_2 , less than 0.45, confers greater advantage in reducing the incidences of air leak syndromes and BPD comparing with a higher FIO_2 (more than 0.45), in the treatment of RDS²¹.

Fluids – We couldn't identify fluids administration as a risk factor of BPD in our patients. The risk of BPD was significantly higher among newborns with higher daily mean fluid administration, but after adjustment for all variables in the model, the difference was not statistically significant (Table I). This may be due in part to the fact of the small size of the sample to identify risk factors of this multifactorial disease. However the excessive fluid intake and/or decreased early weight loss and prolonged PDA are major pathogenic mechanisms for BPD well known. Infants with BPD have increased lung water and are susceptible to gravity-induced collapse and alveolar flooding in the dependent lung with focal tissue damage being distributed inhomogeneously. High fluid volumes in the first days of life may increase neonatal morbidity, being associated to increased risk of PDA. Therefore fluid restriction is a standard treatment in the care of the premature infant, with the goal of reducing BPD risk^{31,41-44}.

Neonatal sepsis – The presence of nosocomial infections during the first month of life increases the risk of BPD in preterm infants

requiring prolonged mechanical ventilation, another risk factor to the disease^{45,46}. Neonatal infection increased also the risk of late death, neurosensory impairment and in extremely low birth weight infants⁴⁷.

In our study, nosocomial sepsis was observed in 81.8% of preterm infants with BPD and in 41.3% of preterm infants without the disease, OR=6.41, 95% CI=2.54-16.14, (Table I). The national average of sepsis in VLBW infants is 35 %¹⁹. Rates of early- and late-onset septicaemia of 5% and 29.4%, respectively, were recently published in VLBW infants⁴⁸.

It is crucial to reduce neonatal sepsis in our preterm infants in all NICUs. As neonatal sepsis is significantly associated with BPD in our patients, in decreasing sepsis we can decrease BPD rate in Portuguese preterm infants. (Table I). With the increasing survival of extremely premature infants there are a large number of them who are developing chronic lung disease, but the severity of the lung damage is considerably less than that observed in the classic form of BPD. Many of these infants have only a mild initial respiratory distress and therefore do not receive aggressive ventilation. So it seems that factors other than oxygen toxicity and mechanical ventilation are involved in the pathogenesis of this new milder type of BPD^{1,45}.

Patent ductus arteriosus – In this study the risk of BPD was significantly higher among newborns with PDA (crude OR=4.48, 95%CI=2.10-9.58), but after adjustment for all variables in the model, the difference was no longer statistically significant (Table I). This may be due in part to the fact of the small size of the sample to identify risk factors of this multifactorial disease.

Clinical and epidemiological data strongly suggest that the presence of a PDA plays a major role in the development of BPD in these infants and accounts for significant morbidity in preterm newborns⁴⁹. For this reason, efforts to prevent BPD in extremely low birth weight infants should include an aggressive approach to an early closure of the PDA hemodynamically significant⁵⁰⁻⁵³. However it has also been assessed that in randomized control trials, neither a significant reduction, nor even a trend towards a reduction on BPD was observed⁵⁴.

Major pathology – In major pathology we included NEC (grade \geq IIA), ROP (grades \geq 3), IVH (grades 3-4) and PVL, because of the few cases in the sample. The *major* pathology observed in our patients was significantly different among the centers

In our study, from the BPD associated pathology (NEC, ROP; IVH and PVL) we looked for, only ROP was significantly associated with BPD, $p < 0.001$, adjusted OR=3.48, 95%CI=1.06-11.41 (Table III). In VLBW infants in Portugal, we found IVH in 27 %, NEC in 10 %, ROP in 9 %, PVL in 6 %, of preterm infants less than 1500 grams¹⁹.

In a recent Spanish study, intraventricular haemorrhage grades 3 to 4 (8.1%) and cystic leukomalacia (2.6%) were the most relevant brain ultrasound findings and NEC was observed in 6.9% of VLBW infants⁴⁸.

In a 10 years period, to investigate trends in mortality and morbidity in very preterm infants there were no changes in the rates of IVH (grades 3-4), ROP (grades \geq 3), seizures or NEC (grade \geq IIA. The increasing rate of sepsis was present in infants < 28 gestational weeks, whereas the increase in BPD was demonstrated in the whole study population < 32 gestational weeks⁴⁹.

Comments

Bronchopulmonary dysplasia has been increasing over the past two decades in parallel with an improvement in the survival ELBW infants. It stems from the interaction of multiple factors that can damage the immature lung. For this reason prevention must be based on the elimination of all the factors implicated in its pathogenesis.

Our data show that in the five centers of the study the prevalence of BPD was 12.9% (33/256) and the most relevant risk factors identified were low birth weight, severe HMD, duration of MV, duration of oxygen therapy and neonatal sepsis.

The implementation of potentially better practices to reduce lung injury in neonates in Portuguese NICUs must be addressed to decrease HMD, mechanical ventilation, oxygen therapy and the prevalence of sepsis. However all NICUs must keep making efforts to assure known better practices, decreasing risk factors and contributing to BPD prevention⁵⁵⁻⁵⁷.

Bibliography

1. Sosenko IRS, Bancalari E. New developments in the presentation, pathogenesis, epidemiology and prevention of bronchopulmonary dysplasia. *In*: Polin RA (Ed.). The Newborn Lung Eduardo Bancalari. Saunders Elsevier 2008; 187-207.
2. Halliday HL, O'Neil CP. What is the evidence for drug therapy in the prevention and management of bronchopulmonary dysplasia? *In*: Bancalari E, Polin RA (Ed.). The newborn lung. Neonatal questions and controversies. Saunders Elsevier 2008; 208-232.
3. Ehrenkranz RA, Walsh MC, Vohr BR, Jobe AH, Wright LL, Fanaroff AA, Wrage LA, Poole K. National Institutes of Child Health and Human Development Neonatal Research Network Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. *Pediatrics* 2005; 116(6):1353-1360.

4. Northway WH Jr, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. *N Engl J Med* 1967; 16:276(7):357-368.
5. Bancalari E, Abdenour GE, Feller R, Gannon J. Bronchopulmonary dysplasia: clinical presentation. *J Pediatr* 1979; 95(5 Pt 2):819-823.
6. Shennan AT, Dunn MS, Ohlsson A, Lennox K, Hoskins EM. Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. *Pediatrics* 1988; 82(4):527-532.
7. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. *Am J Respir Crit Care Med* 2001; 163:1723-1729.
8. MacDonald H. American Academy of Pediatrics. Committee on fetus and newborn. Perinatal care at the threshold of viability. *Pediatrics* 2002; 110: 1024-1027.
9. Ballard JL, Khoury JC, Wedig K, Wang L, Eilers-Walsman BL, Lipp R. New Ballard score, expanded to include extremely premature infants. *J Pediatr* 1991; 119: 417-423.
10. Rudolph AJ, Smith CA. Idiopathic respiratory distress syndrome of the newborn. *J Pediatr* 1960; 57:905-921.
11. Walsh MC, Kliegman RM. Necrotizing enterocolitis: treatment based on staging criteria. *Ped Clin N Am*, 1986; 33:179-201.
12. An International Classification of Retinopathy of Prematurity. *Pediatrics* 1984; 74:127-133.
13. The International Classification of Retinopathy of Prematurity revisited. International Committee for the Classification of Retinopathy of Prematurity. *Arch Ophthalmol* 2005; 123:991-999.
14. Papile LA, Burstein J, Burstein R. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birthweights less than 1500g. *J Pediatr* 1978; 92:529-534.
15. de Vries L, Rennie JM. Preterm brain injury. *In: Rennie JM, Robertson NRC. Textbook of neonatology*, 3rd edition. Churchill Livingstone. London 1999: 1252-1270.
16. Bancalari E, Claure N, Sosenko IR. Bronchopulmonary dysplasia: changes in pathogenesis, epidemiology and definition. *Semin Neonatol* 2003; 8(1):63-71.
17. Walsh MC, Yao Q, Gettner P, Hale E, Collins M, Hensman A, Everette R, Peters N, Miller N, Muran G, Auten K, Newman N, Rowan G, Grisby C, Arnell K, Miller L, Ball B, McDavid G. National Institute of Child Health and Human Development Neonatal Research Network. Impact of a physiologic definition on bronchopulmonary dysplasia rates. *Pediatrics* 2004; 114(5):1305-1311.
18. Walsh M, Engle W, Laptook A, Kazzi SN, Buchter S, Rasmussen M, Yao Q. National Institute of Child Health and Human Development Neonatal Research Network. Oxygen delivery through nasal cannulae to preterm infants: can practice be improved? *Pediatrics* 2005; 116(4):857-861.
19. VLBW infants in Portugal. National Multicenter Study 1996-2000. Portuguese Neonatal Network. *Bial Award of Clinical Medicine* 2002. ISBN 972-99224-0-3.
20. Valcamonico A, Accorsi P, Sanzeni C, Martelli P, La Boria P, Cavazza A, Frusca T. Mid- and long-term outcome of extremely low birth weight (ELBW) infants: an analysis of prognostic factors. *Matern Fetal Neonatal Med* 2007; 20(6):465-471.
21. Speer CP. Inflammation and bronchopulmonary dysplasia: a continuing story. *Semin Fetal Neonatal Med* 2006; 11(5):354-362.
22. Bose CL, Dammann CE, Laughon MM. Bronchopulmonary dysplasia and inflammatory biomarkers in the premature neonate. *Arch Dis Child Fetal Neonatal Ed* 2008; 93(6):F455-F461.
23. Gronckel P, Schmale J, Soditt V, Stützer H, Götze-Speer B, Speer CP. Bronchoalveolar inflammation following airway infection in preterm infants with chronic lung disease. *Pediatr Pulmonol* 2001; 31(5):331-338.
24. Sweet DG, Halliday HL. Modeling and remodeling of the lung in neonatal chronic lung disease: implications for therapy. *Treat Respir Med* 2005; 4(5):347-359.
25. Rocha G, Proença E, Quintas C, Rodrigues T, Guimarães H. Chorioamnionitis and lung damage in the extremely low birth weight infant. *Rev Port Pneumol* 2007; 3(5):745-754.
26. Been JV, Zimmermann LJ. Histologic chorioamnionitis and respiratory outcome in preterm infants. *Arch Dis Child Fetal Neonatal*; Ed. 2009 Jan 8. [Epub ahead of print.]
26. Gortner L, Reiss I, Hilgendorff A. Bronchopulmonary dysplasia and intrauterine growth restriction. *Lancet* 2006; 368(9529):28.
27. Marks KA, Reichman B, Lusky A, Zmora E; Israel Neonatal Network. Fetal growth and postnatal growth

FACTORES DE RISCO DE DISPLASIA BRONCOPULMONAR EM CINCO UNIDADES PORTUGUESAS DE CUIDADOS INTENSIVOS NEONATAIS

Hercília Guimarães, Gustavo Rocha, Gabriela Vasconcellos, Elisa Proença, Maria Luísa Carreira, Maria do Rosário Sossai, Benvinda Morais, Isabel Martins, Teresa Rodrigues, Milton Severo

- failure in very-low-birthweight infants. *Acta Paediatr* 2006; 95(2):236-242.
28. Gortner L, Hilgendorff A, Bähler T, Ebsen M, Reiss I, Rudloff S. Hypoxia-induced intrauterine growth retardation: effects on pulmonary development and surfactant protein transcription. *Biol Neonate* 2005; 88(2):129-135.
29. Kewitz G, Wudel S, Hopp H, Hopfenmüller W, Vogel M, Roots I. Below median birth weight in appropriate-for-gestational-age preterm infants as a risk factor for bronchopulmonary dysplasia. *J Perinat Med* 2008; 36(4):359-364.
30. Sweet D, Bevilacqua G, Carnielli V, Greisen G, Plavka R, Didrik Saugstad O, Simeoni U, Speer CP, Valls-I-Soler A, Halliday H. Working Group on Prematurity of the World Association of Perinatal Medicine, European Association of Perinatal Medicine. European consensus guidelines on the management of neonatal respiratory distress syndrome. *J Perinat Med* 2007; 35(3):175-186.
31. Burch K, Rhine W, Baker R, Litman F, Kaempf JW, Schwarz E, Sun S, Payne NR, Sharek PJ. Implementing potentially better practices to reduce lung injury in neonates. *Pediatrics* 2003; 111(4 Pt 2):e432-e436.
32. Ramanathan R. Optimal ventilatory strategies and surfactant to protect the preterm lungs. *Neonatology* 2008; 93(4):302-308.
33. Ramanathan R, Sardesai S. Lung protective ventilatory strategies in very low birth weight infants. *J Perinatol*. 2008;28(Suppl 1):S41-S46.
34. Bohlin K, Jonsson B, Gustafsson AS, Blennow M. Continuous positive airway pressure and surfactant. *Neonatology* 2008; 93(4):309-315.
35. Patel D, Greenough A. Does nasal CPAP reduce bronchopulmonary dysplasia (BPD)? *Acta Paediatr* 2008; 97(10):1314-1317.
36. Saugstad OD. Take a breath--but do not add oxygen (if not needed). *Acta Paediatr* 2007; 96(6):798-800.
37. Saugstad OD, Ramji S, Soll RF, Vento M. Resuscitation of newborn infants with 21% or 100% oxygen: an updated systematic review and meta-analysis. *Neonatology* 2008; 94(3):176-182.
38. Tin W, Gupta S. Optimum oxygen therapy in preterm babies. *Arch Dis Child Fetal Neonatal*; Ed. 2007; 92(2):F143-F147.
39. STOP-ROP Multicenter Study Group. Supplemental therapeutic oxygen for prethreshold retinopathy of prematurity (STOP-ROP), a randomized controlled trial. I: Primary outcomes. *Pediatrics* 2000; 105:295-310.
40. Sola A. Oxygen in neonatal anesthesia: friend or foe? *Curr Opin Anaesthesiol* 2008; 21(3):332-339.
41. Stevens TP, Harrington EW, Blennow M, Soll RF. Early surfactant administration with brief ventilation vs. selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome. *Cochrane Database Syst Rev* 2007; 17;(4):CD003063.
42. Oh W, Poindexter BB, Perritt R, Lemons JA, Bauer CR, Ehrenkranz RA, Stoll BJ, Poole K, Wright LL. Neonatal Research Network. Association between fluid intake and weight loss during the first ten days of life and risk of bronchopulmonary dysplasia in extremely low birth weight infants. *J Pediatr* 2005; 147(6):786-790.
43. Stephens BE, Gargus RA, Walden RV, Mance M, Nye J, McKinley L, Tucker R, Vohr BR. Fluid regimens in the first week of life may increase risk of patent ductus arteriosus in extremely low birth weight infants. *J Perinatol* 2008; 28(2):123-128.
44. Bell EF, Acarregui MJ. Restricted versus liberal water intake for preventing morbidity and mortality in preterm infants. *Cochrane Database Syst Rev* 2008; (1):CD000503.
45. Gonzalez A, Sosenko IR, Chandar J, Hummler H, Claire N, Bancalari E. Influence of infection on patent ductus arteriosus and chronic lung disease in premature infants weighing 1000 grams or less. *J Pediatr* 1996; 128(4):470-478.
46. Liljedahl M, Bodin L, Schollin J. Coagulase-negative staphylococcal sepsis as a predictor of bronchopulmonary dysplasia. *Acta Paediatr* 2004; 93(2):211-215.
47. Bassler D, Stoll BJ, Schmidt B, Asztalos EV, Roberts RS, Robertson CM, Sauve RS. Using a count of neonatal morbidities to predict poor outcome in extremely low birth weight infants: added role of neonatal infection. *Trial of Indomethacin Prophylaxis in Preterms Investigators*. *Pediatrics* 2009; 123(1):313-318.
48. Moro M, Pérez-Rodríguez J, Figueras-Aloy J, Fernández C, Doménech E, Jiménez R, Pérez-Sheriff V, Quero J, Roques V. Pre-discharge morbidities in extremely and very low-birth-weight infants in Spanish neonatal units. *Am J Perinatol* 2008; 17.
49. Lundqvist P, Källén K, Hallström I, Westas LH. Trends in outcomes for very preterm infants in the

southern region of Sweden over a 10-year period. *Acta Paediatr* 2009; 98(4):648-653.

50. First SIBEN clinical consensus: diagnostic and therapeutic approach to patent ductus arteriosus in premature newborns. Golombek SG, Sola A, Baquero H, Borbonet D, Cabañas F, Fajardo C, Goldsmit G, Lemus L, Miura E, Pellicer A, Pérez JM, Rogido M, Zambosco G, van Overmeire B, Primer Grupo de Consenso Clínico SIBEN (Golombek SG, Sola A, Clyman R, van Overmeire B, Goldsmit G, Natta D, Zambosco G, Miura E, Pérez JM, Weissheimer C, Baquero H, García Harker J, Oviedo Barrantes AN, Morgues M, Tapia JL, Domínguez F, Majano M, Cabañas F, Pellicer A, Cruz H, Fajardo C, Rogido M, Lemus L, Origel AV, Lacarruba JM, Lee M, Tre-sierra J, Guimarães H, Bustos R, Borbonet D, Perales JL. *An Pediatr* 2008; 69(5):454-481.

51. Ohlsson A, Walia R, Shah S. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. *Cochrane Database Syst Rev* 2008; 23;(1):CD003481.

52. Mosalli R, Alfaleh K. Prophylactic surgical ligation of patent ductus arteriosus for prevention of mortality and morbidity in extremely low birth weight infants. *Cochrane Database Syst Rev* 2008; 23;(1):CD006181.

53. McCurnin D, Seidner S, Chang LY, Waleh N, Ikegami M, Petershock J, Yoder B, Giavedoni L, Albertine

KH, Dahl MJ, Wang ZM, Clyman RI. Ibuprofen-induced patent ductus arteriosus closure: physiologic, histologic, and biochemical effects on the premature lung. *Pediatrics* 2008; 121(5):945-956.

54. Tin W, Wiswell TE. Adjunctive therapies in chronic lung disease: examining the evidence. *Semin Fetal Neonatal Med* 2008; 13(1):44-52.

55. Payne NR, LaCorte M, Karna P, Chen S, Finkelstein M, Goldsmith JP, Carpenter JH. Breathsavers Group, Vermont Oxford Network Neonatal Intensive Care Quality Improvement Collaborative. Reduction of bronchopulmonary dysplasia after participation in the Breathsavers Group of the Vermont Oxford Network Neonatal Intensive Care Quality Improvement Collaborative. *Pediatrics* 2006; 118(Suppl 2):S73-S77.

56. Payne NR, LaCorte M, Sun S, Karna P, Lewis-Hunstiger M, Goldsmith JP. Breathsavers Group. Evaluation and development of potentially better practices to reduce bronchopulmonary dysplasia in very low birth weight infants. *Pediatrics* 2006; 118(Suppl 2):S65-S72.

57. Sharek PJ, Baker R, Litman F, Kaempf J, Burch K, Schwarz E, Sun S, Payne NR. Evaluation and development of potentially better practices to prevent chronic lung disease and reduce lung injury in neonates. *Pediatrics* 2003; 111(4 Pt 2):e426-e431.